A first in human study of AVA-011 for the treatment of relapsed or refractory B-cell lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma
Latest Information Update: 07 Jan 2022
Price :
$35 *
At a glance
- Drugs AVA-011 (Primary)
- Indications Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- 04 Jan 2022 According to an Avalon GloboCare media release, this study is on track to initiate by mid 2022.
- 14 May 2020 New trial record
- 08 May 2020 According to an Avalon GloboCare media release, the company has planned to initiate this study in the first quarter of 2021.